Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors

Table 3

Association with metastatic disease at diagnosis (stage IIIB-IV) according to log-rank regression test.

Variable	Univariate			Multivariate
	OR	CI 95%		OR	CI 95%
Male gender	1.296	0.5–3.5	0.611
No syndrome	1.444	0.4–4.8	0.546
GI-NET	2.493	0.9–6.9	0.079			ns
Grading G2	13.364	3.7–47.9	<0.001	77.025	5.6–1064.2	0.001
Low SSTR2A QS	15.400	4.3–55.8	<0.001	121.342	6.8–2174.9	0.001
Low IGF-1R QS	5.727	1.9–16.9	0.002			ns
High p-mTOR QS	12.429	3.1–49.3	<0.001	80.986	4.9–1353.7	0.002

OR: odds ratio; CI: confidence interval; ns: not statistically significant; GI-NET: gastrointestinal primary NET (versus pancreatic NET); SSTR2A: somatostatin receptor 2A; IGF-1R: insulin-like growth factor-1 receptor; p-mTOR: phosphorylated mammalian target of rapamycin; QS: quantitative score.